Long-acting growth hormone (LAGH)

ey0019.4-7 | Long-acting growth hormone (LAGH) | ESPEYB19

4.7. Effective gh replacement with once-weekly somapacitan vs daily GH in children with GHD: 3-year results from REAL 3

L Sa¨vendahl , T Battelino , MH Rasmussen , M Brod , P Saenger , R Horikawa

J Clin Endocrinol Metab, 2022. 107(5): p. 1357-1367. PMID: 34964458Brief Summary: This multicenter, randomized, controlled, phase 2 study compared the effects of once-weekly long-acting growth hormone (GH) somapacitan versus daily GH administered to GH-deficient (GHD) children over a period of 156 weeks. Efficacy estimates were height velocity (HV; cm/y) at year 3 and changes from baseline to end for height SDS, HV SDS, IGF-I SDS, and insulin-li...

1 shares

ey0019.4-8 | Long-acting growth hormone (LAGH) | ESPEYB19

4.8. Weekly lonapegsomatropin in treatment-naive children with growth hormone deficiency: the phase 3 height trial

PS Thornton , AK Maniatis , E Aghajanova , E Chertok , E Vlachopapadopoulou , Z Lin , W Song , E Dam Christoffersen , VM Breinholt , T Kovalenko , E Giorgadze , M Korpal-Szczyrska , PL Hofman , DB Karpf , AD Shu , Beckert M. Michael

J Clin Endocrinol Metab, 2021. 106(11): p. 3184-3195. PMID: 34272849Brief Summary: This randomized, open-label, controlled, phase 3 trial compared the effects of once-weekly long-acting GH lonapegsomatropin versus daily GH in GHD children over a period of 52 weeks. Efficacy was evaluated by height velocity (HV) and height gain from baseline to end. The long-acting formulation showed not only non-inferiority but also superior efficacy compared to...

2 shares

ESPE Yearbook of Paediatric Endocrinology

Yearbook of Paediatric Endocrinology 2022

4. Growth and Growth Factors

4.7. Effective gh replacement with once-weekly somapacitan vs daily GH in children with GHD: 3-year results from REAL 3

4.8. Weekly lonapegsomatropin in treatment-naive children with growth hormone deficiency: the phase 3 height trial

BiosciAbstracts